---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-042770"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2022-11-22T23:59:59+00:00"
generated_at: "2026-06-21T14:30:05.061939+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eterna Therapeutics restructures license with Factor Bioscience, gains right to sublicense three US patents

## Summary
- Amendment dated Nov 22, 2022 grants exclusive sublicensing rights to three US patents (10,662,410, 10,829,738, 10,982,229) from Factor to Brooklyn Immunotherapeutics.
- Prior Novellus-Factor license terminated; Novellus removed and Factor becomes direct licensor to Brooklyn and NoveCite (25% owned by Eterna).
- Brooklyn pays Factor 20% of sublicense fees (first 5-year term) and 30% (potential 2.5-year extension); extension contingent on $100M in sublicense fees.
- License term is 5 years, extendable by 2.5 years; Eterna guarantees all payments and obligations of Brooklyn under the amended agreement.
- Dr. Matthew Angel, Eterna's interim CEO, is co-founder, President, and CEO of Factor Bioscience's parent; transaction is a related-party deal.

## SEC filing metadata
- accession: 0001140361-22-042770
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2022-11-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 1.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000114036122042770/0001140361-22-042770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000114036122042770/brhc10044587_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-042770
- JSON: https://secwatch.observer/filing/0001140361-22-042770.json
- Plain text: https://secwatch.observer/filing/0001140361-22-042770.txt

## Key facts
- Material Agreements
  Ernexa Therapeutics Inc. amended First Amendment with Factor Bioscience Limited (effective 2022-11-22).
  - Action: amendment
  - Agreement: license
  - Counterparty: Factor Bioscience Limited
  - Effective: 2022-11-22
  source text: On November 22, 2022 (the “ Amendment Effective Date ”), Eterna Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a First Amendment (the “ Amendment ”) to the Exclusive License Agreement, dated as of April 26, 2021 (the “ Original License Agreement ,” and as amended by the Amendment, the “ Amended Factor License Agreement ”), by and among Brooklyn Immunotherapeutics LLC, a wholly owned subsidiary of the Company (“ Brooklyn LLC ”), Novellus Therapeutics Limited, a wholly owned subsidiary of the Company (“ Novellus ”), and Factor Bioscience Limited (“ Factor ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036122042770/0001140361-22-042770-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.